IMUNON Reports Third Quarter 2026 Financial Results and Provides Business Update

Imunon, Inc. (IMNN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 IMUNON Reports Third Quarter 2026 Financial Results and Provides Business Update IMNN-001 is the first frontline treatment candidate to demonstrate the potential for a clinically meaningful overall survival benefit in women newly diagnosed with ovarian cancer Enrollm

Event · Earnings
Original reporting
Published Nov 12, 2026, 1:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 12, 2026, 1:04 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$IMNN
Bullish
high confidence
Mentioned
$IMNN
Relevance
8/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$IMNNBullishHigh
01

Why it matters

The disclosed trial data and financial results provide fresh material for traders to reassess valuation and position ahead of the earnings call.

02

Market read

First‑report of quarterly earnings and pivotal trial updates; likely to move IMNN and related biotech stocks.

03

What to watch

Debt‑for‑equity exchange and loss of ThermoDox rights may constrain cash flow and dilute shareholders.

Relevance 8/10Novelty 9/10Timing: pre-market today
AlphAI · Earnings readIMNN · Q3 2026 · ended 2026-09-30

Imunon reports Q3 2026 net loss available to common shareholders of $3.8 million, or $0.64 per share, versus $1.16 per share a year earlier, and cash of $4.0 million at September 30, 2026

↓Weak quarter

The filing shows no revenue and no guidance. Operating expenses were roughly flat, but per-share loss narrowed only because of a much larger share count, total stockholders' equity fell from $7.062 million to $2.622 million, and unrestricted cash of $4.039 million sits against a company that reports a nine-month net cash use of $10.2 million.

EPS · GAAP
$(0.64)

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Total operating expenses (Q3 2026, three months ended Sep 30)GAAP$3.45M––
Research and development expenses (Q3 2026)GAAP$1.79M––
General and administrative expenses (Q3 2026)GAAP$1.66M––
Loss from operations (Q3 2026)GAAP−$3.45M––
Other (expense) income (Q3 2026)GAAP−$302K––
Net loss (Q3 2026)GAAP−$3.75M––
Deemed dividend on preferred stock (Q3 2026)GAAP−$63K––
Net loss available to common shareholders (Q3 2026)GAAP−$3.81M––
Net loss available to common shareholders per share, basic and diluted (Q3 2026)GAAP$(0.64)––
Research and development expenses (nine months ended Sep 30, 2026)GAAP$5.59M––
General and administrative expenses (nine months ended Sep 30, 2026)GAAP$4.95M––
Total operating expenses (nine months ended Sep 30, 2026)GAAP$10.55M––
Loss from operations (nine months ended Sep 30, 2026)GAAP−$10.55M––
Other (expense) income (nine months ended Sep 30, 2026)GAAP−$267K––
Net loss (nine months ended Sep 30, 2026)GAAP−$10.81M––
Deemed dividend on preferred stock (nine months ended Sep 30, 2026)GAAP−$82K––
Net loss available to common shareholders (nine months ended Sep 30, 2026)GAAP−$10.89M––
Net loss available to common shareholders per share, basic and diluted (nine months ended Sep 30, 2026)GAAP$(2.01)––
Net cash used in operating activities (nine months ended Sep 30, 2026)GAAP$10.2M––
Cash and cash equivalents (Sep 30, 2026, versus Dec 31, 2025)GAAP$4.04M––
Restricted cash (Sep 30, 2026)GAAP$5.04M––
Total assets (Sep 30, 2026, versus Dec 31, 2025)GAAP$12.01M––
Total liabilities (Sep 30, 2026, versus Dec 31, 2025)GAAP$9.39M––
Total stockholders' equity (Sep 30, 2026, versus Dec 31, 2025)GAAP$2.62M––

Capital returns

  • No share repurchases or dividends on common stock are reported in the filing.
  • On September 29, 2026, the Company entered into an Exchange Agreement under which $1.2 million of outstanding debt, together with accrued and unpaid interest, was exchanged for shares of newly designated, non-convertible Series B Preferred Stock. The Company states the transaction reduces the outstanding balance of the A-1 Note by approximately 43%, increases stockholders' equity and involves no issuance of common stock or warrants.
  • The income statement shows a deemed dividend on preferred stock of $(63) thousand in Q3 2026 and $(82) thousand for the nine months ended September 30, 2026.

What drove it

  • The Company states that Q3 2026 clinical costs for the OVATION studies were $0.4 million, compared with $0.5 million a year earlier, and that as enrollment in OVATION 3 advanced these costs were offset by lower manufacturing and clinical supply costs and lower other clinical and regulatory costs.
  • The Company states that Q3 2026 general and administrative expenses increased to $1.7 million from $1.6 million, primarily reflecting higher outside professional fees.
  • The Company states that nine-month R&D rose to $5.6 million from $5.3 million, with manufacturing and clinical supply costs for the OVATION and MRD programs increasing to $3.3 million from $3.0 million, partially offset by lower costs associated with the MRD Study and the closeout of the OVATION 2 Study.
  • Other (expense) income moved to $(302) thousand in Q3 2026 from $47 thousand in Q3 2025. The filing prints the line but does not explain the change.
  • On October 21, 2026, the Company agreed to sell its rights to ThermoDox to VoxelDox Therapeutics, Inc. In exchange the Company would receive an equity stake, payments of up to $16.5 million contingent on development milestones, and royalties on future net sales after approval. Closing is contingent on VoxelDox raising $2.5 million in funding.
  • On September 10, 2026, the Company entered into a CRADA with the National Cancer Institute, under which NCI's CTEP will assume regulatory sponsorship of IMNN-001 development.

Concerns

  • The Company reported cash and cash equivalents of $4,039 thousand at September 30, 2026, against a nine-month net cash use from operations of $10.2 million. The filing does not describe how the Company will fund operations beyond the cash it reports.
  • Total stockholders' equity declined from $7,062 thousand at December 31, 2025 to $2,622 thousand at September 30, 2026, while total liabilities rose from $5,226 thousand to $9,386 thousand.
  • The Company filed a Form S-1 on October 27, 2026 for a proposed securities offering. The registration statement has not yet become effective.
  • The ThermoDox sale depends on VoxelDox raising $2.5 million, so the proceeds and the $16.5 million in potential milestone payments are contingent.
  • The weighted average share count rose sharply versus the prior year period, which lowered the loss per share even though the net loss increased. Per-share figures are not comparable with the prior year without the share count context.
  • The forward-looking statements section warns that interim clinical results are not necessarily indicative of final results.

What to watch

  • Whether the S-1 offering becomes effective and the size and terms of any financing relative to the $4.0 million of unrestricted cash and the $5.0 million of restricted cash.
  • Whether VoxelDox completes the $2.5 million raise that is a condition of the ThermoDox sale.
  • Enrollment progress in OVATION 3, which the Company expects to complete by the first quarter of 2029, and the two planned interim analyses.
  • Trend in G&A, which the Company attributes to higher outside professional fees, and in manufacturing and clinical supply costs for the OVATION and MRD programs.
  • Further results from the IMNN-001 Phase 2 OVATION 2 data and the Phase 2 MRD study, including the translational data presented at SITC 2026.

Balance sheet and cash flow

  • Cash and cash equivalents were $4.0 million at September 30, 2026 (printed as $4,039 thousand), compared with $8,781 thousand at December 31, 2025.
  • The Company held an additional $5.0 million of restricted cash at September 30, 2026 (printed as $5,039 thousand), shown under other assets. The balance sheet shows no restricted cash at December 31, 2025.
  • Net cash used in operating activities was $10.2 million for the nine months ended September 30, 2026, which the filing describes as unchanged from the same period last year. The prior-year figure is not printed in the text.
  • Note payable current portion (Note A) was $1,380 thousand and Note Payable (Note B) noncurrent was $4,884 thousand at September 30, 2026. The balance sheet shows no notes payable at December 31, 2025.
  • Accounts payable and accrued liabilities fell from $4,217 thousand at December 31, 2025 to $2,414 thousand at September 30, 2026.
  • Preferred stock, including additional paid-in capital, was $3,384 thousand at September 30, 2026, against nil at December 31, 2025.
  • Accumulated deficit rose from $(421,298) thousand to $(432,111) thousand.

Analysis

Imunon's Q3 2026 release contains no revenue line and no guidance. The results are an operating loss and a net loss. Total operating expenses were $3,448 thousand in Q3 2026 against $3,476 thousand a year earlier, and R&D fell to $1,793 thousand from $1,899 thousand while G&A rose to $1,655 thousand from $1,577 thousand. The Company attributes the G&A increase primarily to higher outside professional fees. Net loss was $(3,750) thousand, and net loss available to common shareholders was $(3,813) thousand after a $(63) thousand deemed dividend on preferred stock. The reported loss per share was $(0.64), compared with $(1.16) a year earlier. The nine-month figures show a similar pattern: total operating expenses of $10,546 thousand against $10,389 thousand, and a net loss available to common shareholders of $(10,895) thousand against $(10,272) thousand. Nine-month loss per share was $(2.01) against $(5.53).

The per-share comparison needs care. The weighted average share count in the statement of operations rose from 2,944 thousand in Q3 2025 to 5,947 thousand in Q3 2026, and from 1,856 thousand to 5,408 thousand over the nine months. The filing does not explain this change in its text. The narrower loss per share therefore reflects a larger share count on a net loss that increased, and the two per-share figures should not be read as an improvement in underlying loss.

The balance sheet shows the financing pressure more clearly than the income statement. Cash and cash equivalents were $4,039 thousand at September 30, 2026, against $8,781 thousand at December 31, 2025, and the Company reports a further $5,039 thousand of restricted cash that sits in other assets. Net cash used in operating activities was $10.2 million for the nine months, which the filing describes as unchanged from the prior year period. Total liabilities rose to $9,386 thousand from $5,226 thousand, with notes payable now carried as Note A ($1,380 thousand current) and Note B ($4,884 thousand noncurrent). Total stockholders' equity fell to $2,622 thousand from $7,062 thousand. The September 29 exchange of $1.2 million of debt into Series B Preferred Stock is described by the Company as reducing the A-1 Note balance by approximately 43% and increasing stockholders' equity, and the balance sheet shows preferred stock of $3,384 thousand.

Strategically, the Company reports three changes: the October 21 agreement to transfer ThermoDox rights to VoxelDox in exchange for equity, milestone payments of up to $16.5 million and royalties, all conditional on VoxelDox raising $2.5 million; the September 10 CRADA under which NCI's CTEP will assume regulatory sponsorship of IMNN-001; and the October 27 Form S-1 filing for a proposed offering that has not yet become effective. Management frames the debt exchange and ThermoDox transaction as capital allocation steps that preserve financial flexibility. The filing does not state how long current cash and restricted cash will fund operations, and no going concern language appears in the text provided.

The investment case in this release rests on IMNN-001 and the OVATION 3 Phase 3 trial, which the Company says is expected to complete enrollment by the first quarter of 2029. The release describes Phase 2 OVATION 2 translational data, a DSMB recommendation to continue the MRD study without modification, and a poster at SITC 2026. These are development milestones and carry no reported financial value in this filing. The verdict is weak because the reported cash position, the equity decline and the pending equity offering weigh more heavily than the stable operating expense base in this quarter.

Management, verbatim

IMUNON continues to make significant progress in the clinical development of IMNN-001 for advanced ovarian cancer.

Stacy R. Lindborg, Ph.D., President and Chief Executive Officer

Through our agreement to transition ThermoDox ® to a dedicated development partner and our recent debt-for-equity exchange, we are demonstrating the disciplined approach to capital allocation that we believe is essential to advancing our most significant clinical opportunity while preserving opportunities for future value creation.

Stacy R. Lindborg, Ph.D., President and Chief Executive Officer

Not in the filing

stated, not guessed
  • Prior-year percentage changes for any line item (none printed)
  • Prior-year figure for nine-month net cash used in operating activities (the text says unchanged but does not print the number)
  • Q3 2026 and nine-month cash flow statement lines, other than net cash used in operating activities
  • Prior-quarter (Q2 2026) comparatives for any line item
  • Revenue, gross margin and cost of sales (no revenue line is reported)
  • Financial guidance or outlook for 2026 or later periods
  • Period-specific comparison of balance sheet items against September 30, 2025
  • Explanation of the change in other (expense) income
  • Size and terms of the proposed S-1 offering
  • Share count at period end and common shares outstanding (only weighted averages are printed)
  • The previous outlook covered enrollment timing for a study in the first half of 2029, which is a later period and not a reported metric, so there is nothing to compare for this quarter.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Background

Imunon is a clinical‑stage biotech focused on DNA‑mediated immunotherapy for ovarian cancer.

Company-level read

Ticker impact

$IMNNBullishHigh confidence
Context

Imunon reported Q3 2026 results and disclosed positive Phase 2 data and ongoing Phase 3 trial progress for its lead candidate IMNN-001.

Expected impact

likely upward pressure as market prices in favorable clinical data and improved financial outlook

Evidence & confidence

First disclosure of Phase 2 survival benefit and continued Phase 3 enrollment, combined with a narrowing net loss, typically drives biotech stocks higher.

Market effects

strengthens outlook for DNA‑mediated immunotherapy sector and may lift peers developing similar IL‑12 platforms.

positive for US biotech investors and Nasdaq biotech indices.

limited to biotech niche; no broad macro effect.

Counterpoint

If Phase 3 fails to meet interim endpoints, the stock could face sharp downside despite current optimism.

Key entities

  • Imunon, Inc.

    NASDAQ‑listed biotech reporting Q3 2026 results.

  • National Cancer Institute

    Partner in CRADA supporting IMNN-001 development.

Every IMNN earnings report

This story covers one filing. The ticker page keeps them all: each quarter's reported metrics with year-over-year and sequential comparisons, segments, guidance, and how the numbers landed against the company's own prior outlook.

Related articles

$IMNNMedAI 8/10

Imunon (IMNN) Q3 2026 Earnings Call Transcript

Imunon (IMNN) reported Q3 2026 progress, highlighting Phase III IMNN-001 study for ovarian cancer. The company saw strong enrollment, independent validation, and a partnership with the National Cancer Institute. IMNN-001 aims to address a disease with low survival rates and limited treatment advances. The company expects 50% enrollment by Q1 2028 and completion by Q1 2029, with interim analysis in Q1 2030.

$IMNNLow

Imunon 3Q 2026: EPS ($0.64) — 10-Q Summary

Imunon (IMNN) reported a wider net loss of $3.81M in Q3 2026, though diluted EPS improved to ($0.64) from ($1.16) YoY. Operating expenses decreased 1%, with R&D costs down 6%. The OVATION 3 trial enrollment exceeded expectations, and the company advanced its NCI collaboration and MRD study. Imunon discontinued PLACCINE and IMNN-101 development in Q1 2026.

$IMNNMed

Imunon Reports Q3 2026 Net Loss of $3.8 Million and Advances IMNN-001

Imunon reported a Q3 2026 net loss of $3.8M, or $0.64 per share, compared to $3.4M, or $1.16 per share, a year earlier. Operating expenses were $3.4M. The company updated its Phase 3 ovarian cancer study and other programs, with enrollment expected to complete by Q1 2029. Imunon also transferred ThermoDox rights to VoxelDox, contingent on funding.

$IMNNHighAI 8/10

IMUNON presents translational data from ovarian cancer trial

IMUNON Inc. (IMNN) presented data from its Phase 2 OVATION 2 study of IMNN-001 in advanced ovarian cancer, showing improved survival and immune response. The trial compared IMNN-001 with chemotherapy against chemotherapy alone. The company is now conducting a Phase 3 trial, OVATION 3, to confirm these results. IMNN-001 is a DNA-based immunotherapy targeting IL-12 delivery to tumor tissue.

$IMNNMed

In an ovarian cancer trial, median survival was 14.7 months longer with added treatment

IMUNON, Inc. (Nasdaq: IMNN) announced new data from its Phase 2 OVATION 2 study, showing that IMNN-001 increased anti-tumoral T-cell activity in ovarian cancer patients. The treatment improved median overall survival by 14.7 months compared to standard care. The findings support the ongoing Phase 3 OVATION 3 trial. The data was presented at the Society for Immunotherapy of Cancer (SITC) 41st Annual Meeting.

$IMNNMedAI 8/10

Imunon (IMNN) Q2 2026 Earnings Call Transcript

Imunon (IMNN) held its Q2 2026 earnings call. Management reported Phase 2 OVATION II median overall survival of 45.1 months vs 30.4 months, and PARP maintenance survival of 65.6 vs 41.4 months. Q2 R&D was $1.5M, G&A $1.3M, net loss $2.8M. Cash was $6.9M after a $10M financing.